FDA NDC
Adbry
This name is from the loaded FDA file.
Source: FDA NDC Directory, live from openFDA. Publisher page
- NDC
- 50222-350
- Proprietary name
- Adbry
- Nonproprietary name
- tralokinumab-ldrm
- Labeler
- LEO Pharma Inc.
- Dosage form
- INJECTION, SOLUTION
- Strength
- 300 mg/2mL
Run it in Rivvi
Which 2027 plans near you dropped or restricted tralokinumab-ldrm?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan, from the CMS Part D files.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.